An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer (ICON6)

This study is ongoing, but not recruiting participants.

Sponsor:

Collaborators:

Cancer Research UK

National Health and Medical Research Council, Australia

ANZGOG

NCIC Clinical Trials Group

Grupo Español de Investigación en Cáncer de Ovario

AstraZeneca

Information provided by (Responsible Party):

Andrew Embleton, Medical Research Council

ClinicalTrials.gov Identifier:

NCT00532194

First received: September 19, 2007

Last updated: September 21, 2015

Last verified: September 2015

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	December 2016
Primary Completion Date:	April 2013 (Final data collection date for primary outcome measure)

Publications:

Ledermann J, Perren T, Raja F, Embleton A, Rustin GJS, Jayson G, Kaye SB, Swart AM, Vaughan M, Hirte H. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial. Eur J Cancer 2013;49(Suppl. 3):S5 (LBA10).

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB; ICON6 collaborators. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Mar 12;387(10023):1066-1074. doi: 10.1016/S0140-6736(15)01167-8. Erratum in: Lancet. 2016 Apr 23;387(10029):1722.

To Top